Tarpeyo® (budesonide) – Updated indication, accelerated approval converted to full approval
December 20, 2023 - Calliditas Therapeutics announced the full FDA approval of Tarpeyo (budesonide), to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
Top